Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Stephen Brannan, MD

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on the phase II clinical data for KarXT, published in the 

Journal Publication Brings Good News for Novel Schizophrenia Treatment

is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Videos

Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment. 

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.

To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see 

Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia. 